

Prof. YEŞİM ERALP

Personal Information

Email: Yesim.Eralp@acibadem.edu.tr

Web: <https://avesis.acibadem.edu.tr/Yesim.Eralp>

Education Information

Post Doctorate of Medicine, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , Turkey 1998 - 2001

Expertise In Medicine, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , Turkey 1992 - 1998

Academic Titles / Tasks

Associate Professor, Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, 2004 - 2009

Expert, Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, 2001 - 2005

Expert, Istanbul University, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 1992 - 1997

Lecturer PhD, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , 1985 - 1991

Academic and Administrative Experience

Istanbul University, 2006 - 2010

Courses

TÜMÖR İMMÜNOLOJİSİ VE İMMÜNÖTERAPİ, Undergraduate, 2016 - 2017

5. SINIF ONKOLOJİ UYGULAMA, Undergraduate, 2016 - 2017

OVER TÜMÖRLERİ, Postgraduate, 2016 - 2017

HEDEFE YÖNELİK İMMUN ve GEN TEDAVİDE TEMEL İLKELER, Undergraduate, 2016 - 2017

ONKOLOJİDE HEDEFE YÖNELİK TEDAVİ, Undergraduate, 2016 - 2017

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group**
DOĞAN İ., AKSOY S., ÇAKAR B., BAŞARAN G., Ercelep O., Mandel N. M., KORKMAZ T., Gokmen E., ŞENER C., AYDINER A., et al.
CANCERS, no.6, 2023 (SCI-Expanded)
- II. **Lung Cancer in Turkey**
KAYI CANGIR A., Yumuk P. F., SAK S., AKYÜREK S., ERALP Y., Yilmaz U., Selek U., EROĞLU A., TATLI A. M., Dincbas F. O., et al.
JOURNAL OF THORACIC ONCOLOGY, vol.17, no.10, pp.1158-1170, 2022 (SCI-Expanded)
- III. **Application of mRNA Technology in Cancer Therapeutics**

ERALP Y.

VACCINES, vol.10, no.8, 2022 (SCI-Expanded)

- IV. **Laterality and survival in mesothelioma: A SEER database analysis.**
Parekh J., Yerlikaya A., Xie Y., Eralp Y., Adjepong Y.
JOURNAL OF CLINICAL ONCOLOGY, no.16, 2022 (SCI-Expanded)
- V. **International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials**
Smeltzer M. P., Scagliotti G., Wakelee H. A., Mitsudomi T., Roy U. B., Clark R. C., Arndt R., Pruett C. D., Kelly K. L., Ujhazy P., et al.
JOURNAL OF THORACIC ONCOLOGY, vol.17, no.5, pp.651-660, 2022 (SCI-Expanded)
- VI. **Factors predicting a lower likelihood of residual nodal disease in clinically-node positive patients undergoing sentinel node surgery after neoadjuvant chemotherapy for breast cancer**
Cabioglu N., KARANLIK H., Igci A., Muslumanoglu M., TÜKENMEZ M., EMİROĞLU S., Ozkurt E., Onder S., Saip P., Eralp Y., et al.
CANCER RESEARCH, no.4, 2022 (SCI-Expanded)
- VII. **Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center**
AK N., Toker A., KARA M., ÖZKAN B., Ulker M., Kaba E., YEGEN G., KARAMAN Ş., Dagoglu N., Saglam E. K., et al.
TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, vol.29, no.4, pp.487-495, 2021 (SCI-Expanded)
- VIII. **The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study.**
Ak N., Ozkan B., Yenigun M. B., Yilmazbayhan D., Toker A., Ferhatoglu F., Yasar A., SAK S., Tanju S., Dilege S., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.26, no.3, pp.819-829, 2021 (SCI-Expanded)
- IX. **TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer**
CABIOĞLU N., ÖNDER S., Oner G., Karatay H., TÜKENMEZ M., Muslumanoglu M., Igci A., Eralp Y., AYDINER A., Saip P., et al.
BMC CANCER, vol.21, no.1, 2021 (SCI-Expanded)
- X. **GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients**
Peled N., Gillis R., Kilickap S., Froesch P., Orlov S., Filippova E., Demirci U., Christopoulos P., Cicin I., Basal F. B., et al.
JOURNAL OF THORACIC ONCOLOGY, vol.16, no.3, 2021 (SCI-Expanded)
- XI. **Tim3 expression on tumor infiltrating lymphocytes is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple negative breast cancer**
CABIOĞLU N., ÖNDER S., Oner G., Karatay H., TÜKENMEZ M., Muslumanoglu M., Igci A., Eralp Y., AYDINER A., SAİP P. M., et al.
CANCER RESEARCH, no.4, 2021 (SCI-Expanded)
- XII. **GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients**
Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., Demirci U., Christopoulos P., ÇİÇİN İ., Basal F. B., et al.
LUNG CANCER, vol.148, pp.48-54, 2020 (SCI-Expanded)
- XIII. **Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial**
Demir A., Mandel N. M., PAYDAŞ S., Demir G., ER O., Turhal N. S., Bavbek S., Eralp Y., Saip P. M., Guler E. N., et al.
Balkan medical journal, vol.37, no.2, pp.104-107, 2020 (SCI-Expanded)
- XIV. **Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients**
Papadopoulou E., Tsoulos N., Tsantikidi K., Metaxa-Mariatou V., Stamou P. E., Kladi-Skandali A., Kapeni E., Tsaousis G., Pentheroudakis G., Petrakis D., et al.
PLOS ONE, vol.14, no.12, 2019 (SCI-Expanded)

- XV. **The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study**
Eralp Y., AK N., Yilmazbayhan D., ÖZKAN B., FERHATOĞLU F., DEMİRKAZIK A., SAK S., Dilege S., Tanju S., Toker A., et al.
JOURNAL OF THORACIC ONCOLOGY, no.10, 2019 (SCI-Expanded)
- XVI. **Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey**
Kilickap S., Demirci U., Bugdayci F., Tural D., KORKMAZ T., PAYDAŞ S., Yilmaz C., TURNA Z. H., Sezer A., Cinkir H. Y., et al.
JOURNAL OF THORACIC ONCOLOGY, no.10, 2019 (SCI-Expanded)
- XVII. **Outcomes of Thymoma and Determinants of Survival: 16 Years Experience of a Tertiary Cancer Center**
AK N., Toker A., Bayraktar S., ÖZKAN B., ÜLKER M. G., Dagoglu N., KARAMAN S., Kaba E., FERHATOĞLU F., AYDIN E. M., et al.
JOURNAL OF THORACIC ONCOLOGY, no.10, 2019 (SCI-Expanded)
- XVIII. **Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey**
Kilickap S., Ozturk A., Karadurmus N., Korkmaz T., Yumuk P., ÇİÇİN İ., PAYDAŞ S., Cilbir E., Sakalar T., Uysal M., et al.
JOURNAL OF THORACIC ONCOLOGY, no.10, 2018 (SCI-Expanded)
- XIX. **Possible role of stress, coping strategies, and life style in the development of breast cancer**
YILDIRIM N., ÖZKAN M., Ilgun A. S., Sarsenov D., Alco G., Aktepe F., KALYONCU N., Izci F., Selamoglu D., Ordu C., et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE, vol.53, no.3, pp.207-220, 2018 (SCI-Expanded)
- XX. **Preoperative Lymphedema-Related Risk Factors in Early-Stage Breast Cancer**
Iyigun Z. E., Duymaz T., Ilgun A. S., Alco G., Ordu C., Sarsenov D., Aydin A. E., Celebi F. E., Izci F., Eralp Y., et al.
LYMPHATIC RESEARCH AND BIOLOGY, vol.16, no.1, pp.28-35, 2018 (SCI-Expanded)
- XXI. **Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients**
Ilgun S., Sarsenov D., Erdogan Z., Ordu C., Celebi F., Pilanci K. N., Ozturk A., Selamoglu D., Alco G., Aktepe F., et al.
JOURNAL OF BUON, vol.21, no.6, pp.1425-1432, 2016 (SCI-Expanded)
- XXII. **Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy**
Sen F., Tambas M., Ozkaya K., Guveli M. E., Ciftci R., Ozkan B., ORAL E. N., KAYTAN SAĞLAM E., Saip P., Toker A., et al.
MEDICINE, vol.95, no.30, 2016 (SCI-Expanded)
- XXIII. **Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer Survival and Response to Treatment**
AYDINER A., Sen F., Tambas M., Ciftci R., Eralp Y., Saip P., Karanlik H., Fayda M., Kucucuk S., ÖNDER S., et al.
MEDICINE, vol.94, no.52, 2015 (SCI-Expanded)
- XXIV. **The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer**
ÖZMEN V., ÖZÇINAR B., Bozdogan A., Eralp Y., YAVUZ E., DİNÇER M. Z.
EJSO, vol.41, no.10, pp.1368-1372, 2015 (SCI-Expanded)
- XXV. **Is Administration of Trastuzumab an Independent Risk Factor for Developing Osteonecrosis of the Jaw Among Metastatic Breast Cancer Patients Under Zoledronic Acid Treatment?**
Pilanci K. N., Alco G., Ordu C., Sarsenov D., Celebi F., Erdogan Z., Agacayak F., Ilgun S., Tecimer C., Demir G., et al.
MEDICINE, vol.94, no.18, 2015 (SCI-Expanded)
- XXVI. **Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy**
GEZER U., Keskin S., Igci A., TÜKENMEZ M., Tiryakioglu D., Cetinkaya M., Disci R., Dalay N., Eralp Y.
ONCOLOGY LETTERS, vol.8, no.2, pp.845-848, 2014 (SCI-Expanded)
- XXVII. **Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on**

determination of epithelial ovarian carcinoma?

Karabulut S., Aksit E., Tas F., Ciftci R., Aydinler A., Yildiz İ., Keskin S., Eralp Y., Yasasever C. T., Vatansever S., et al.
TUMOR BIOLOGY, vol.35, no.5, pp.4323-4329, 2014 (SCI-Expanded)

XXVIII. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer

Yildiz İ., Tas F., Kilic L., Sen F., Saip P., Eralp Y., Keskin S., Karabulut S., Ciftci R., Serilmez M., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.72, no.2, pp.437-444, 2013 (SCI-Expanded)

XXIX. Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2 alpha Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer

Eralp Y., Keskin S., YÖRÜKER E. E., Akisik E., Igci A., Muslumanoglu M., Yilmaz S., Tunaci M., Camlica H., Tuzlali S., et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.36, no.3, pp.215-223, 2013 (SCI-Expanded)

XXX. Association of clinical and pathological variables with survival in thymoma

AYDINER A., Toker A., Sen F., Bicakci E., KAYTAN SAĞLAM E., Erus S., Eralp Y., TAŞ F., ORAL E. N., Topuz E., et al.
MEDICAL ONCOLOGY, vol.29, no.3, pp.2221-2228, 2012 (SCI-Expanded)

XXXI. Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non-Small-Cell Lung Cancer: A Phase II Study

Aydiner A., Sen F., KAYTAN SAĞLAM E., Oral E. N., Eralp Y., TAŞ F., Toker A., Dilege S.
CLINICAL LUNG CANCER, vol.12, no.5, pp.286-292, 2011 (SCI-Expanded)

XXXII. Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy

Keskin S., Muslumanoglu M., Saip P., Karanlik H., Guveli M., Pehlivan E., Aydogan F., Eralp Y., AYDINER A., Yavuz E., et al.
ONCOLOGY, vol.81, no.1, pp.30-38, 2011 (SCI-Expanded)

XXXIII. Yolk sac tumours of the ovary: Evaluation of clinicopathological features and prognostic factors

Cicin I., Saip P., Guney N., Eralp Y., Ayan I., KEBUDİ R., Topuz E.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, vol.146, no.2, pp.210-214, 2009 (SCI-Expanded)

XXXIV. Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis

Saip P., Cicin I., Eralp Y., Karagol H., Kucucuk S., Alas R. C., Yavuz E., Dincer M., KAYTAN SAĞLAM E., Topuz E.
JOURNAL OF NEURO-ONCOLOGY, vol.93, no.2, pp.243-251, 2009 (SCI-Expanded)

XXXV. Malignant Ovarian Germ Cell Tumors A Single-Institution Experience

Cicin I., Eralp Y., Saip P., Ayan I., Kebudi R., Iyibozyurt C., Tuzlali S., GÖRGÜN Ö. N. H., Topuz E.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.32, no.2, pp.191-196, 2009 (SCI-Expanded)

XXXVI. Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer.

Karagol H., Saip P., Eralp Y., Topuz S., Berkman S., İlhan R., Topuz E.
Tumori, vol.95, pp.207-11, 2009 (SCI-Expanded)

XXXVII. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger

Eralp Y., Smith T. L., Altundag K., Kau S., Litton J., Valero V., Buzdar A., Hortobagyi G. N., Arun B.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.135, no.1, pp.141-148, 2009 (SCI-Expanded)

XXXVIII. Factors affecting the prognosis of breast cancer patients with brain metastases

Saip P., Cicin I., Eralp Y., Kucucuk S., Tuzlali S., Karagol H., Aslay I., Topuz E.
BREAST, vol.17, no.5, pp.451-458, 2008 (SCI-Expanded)

XXXIX. Impact of adjuvant chemotherapy with respect to level of hormone receptor expression in patients with hormone responsive breast cancer: Implications for endocrine resistance

Eralp Y., Sakallioğlu B., Kucucuk S., Tuzlali S., Saip P., Igci A., Muslumanoglu M., Aydiner A., Topuz E.

JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (SCI-Expanded)

- XL. **Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer**
Derin D., Eralp Y., Ozluk Y., Yavuz E., Guney N., Saip P., Igci A., ÖZMEN V., Kucucuk S., Aslay I., et al.
CANCER INVESTIGATION, vol.26, no.7, pp.671-679, 2008 (SCI-Expanded)
- XLII. **Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer**
GEZER U., Eralp Y., Akisik E. Z., YÖRÜKER E. E., Saip P., Topuz E., Dalay N.
CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM V, vol.1137, pp.175-179, 2008 (SCI-Expanded)
- XLIII. **Leptomeningeal dissemination of ovarian carcinoma through a ventriculopenitoneal shunt**
Eralp Y., Saip P., Aydin Z., Berkman S., Topuz E.
GYNECOLOGIC ONCOLOGY, vol.108, no.1, pp.248-250, 2008 (SCI-Expanded)
- XLIV. **Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy**
GEZER U., Eralp Y., YÖRÜKER E. E., Akisik E. Z., Saip P., Topuz E., Dalay N.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, vol.46, no.3, pp.311-317, 2008 (SCI-Expanded)
- XLV. **Multifocal breast cancer in women ≤ 35 years old**
Litton J. K., Eralp Y., Gonzalez-Angulo A. M., Broglio K., Uyei A., Hortobagyi G. N., Ann B.
CANCER, vol.110, no.7, pp.1445-1450, 2007 (SCI-Expanded)
- XLVI. **Women age ≤ 35 years with primary breast carcinoma - Disease features at presentation**
Gonzalez-Angulo A., Broglio K., Kau S., Eralp Y., Erlichman J., Valero V., Theriault R., Booser D., Buzdar A., Hortobagyi G., et al.
CANCER, vol.103, no.12, pp.2466-2472, 2005 (SCI-Expanded)
- XLVII. **Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer**
Oral E., Aydiner A., Eralp Y., Topuz E.
MEDICAL ONCOLOGY, vol.22, no.4, pp.367-374, 2005 (SCI-Expanded)
- XLVIII. **Thymidine labeling index: Prognostic role in breast cancer**
Bilir A., Eralp Y., CABIOĞLU N., Agizhali B., Camlica H., Aydiner A.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.27, no.4, pp.400-406, 2004 (SCI-Expanded)
- XLIX. **Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer - Consolidative intraperitoneal cisplatin in ovarian cancer**
Topuz E., Eralp Y., Saglam S., Saip P., Aydiner A., Berkman S., Yavuz E.
GYNECOLOGIC ONCOLOGY, vol.92, no.1, pp.147-151, 2004 (SCI-Expanded)
- L. **Women aged 35 years or younger with primary breast carcinoma: Disease features at presentation**
Gonzalez-Angulo A. M., Broglio K., Eralp Y., Kau S., Erlichman J., Valero V., Booser D., Buzdar A. U., Hortobagyi G. N., Arun B.
ANNALS OF ONCOLOGY, vol.15, pp.58, 2004 (SCI-Expanded)
- LI. **Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model**
Eralp Y., Wang X., Wang J., Maughan M., Polo J., Lachman L.
BREAST CANCER RESEARCH, vol.6, no.4, 2004 (SCI-Expanded)
- LII. **Prognostic factors in localized soft-tissue sarcomas.**
Kaytan E., Yaman F., Cosar R., Eralp Y., Saip P., Darendeliler E.
American journal of clinical oncology, vol.26, pp.411-5, 2003 (SCI-Expanded)
- LIII. **Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix**
Eralp Y., Saip P., Sakar B., Kucucuk S., Aydiner A., Dincer M., Aslay I., Topuz E.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol.13, no.4, pp.497-504, 2003 (SCI-Expanded)

- LIII. **Resectable thymoma: Treatment outcome and prognostic factors in the late adolescent and adult age group**
Eralp Y., Aydiner A., Kizir A., Kaytan E., Oral E., Topuz E.
CANCER INVESTIGATION, vol.21, no.5, pp.737-743, 2003 (SCI-Expanded)
- LIV. **Prognostic factors and survival in late adolescent and adult patients with small round cell tumors**
Eralp Y., Bavbek S., Başaran M., Kaytan E., Yaman F., Bilgiç B., Darendeliler E., Onat H.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.25, no.4, pp.418-424, 2002 (SCI-Expanded)
- LV. **Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100) - A phase II study**
Basaran M., Bavbek E., Sakar B., Eralp Y., Alici S., TAŞ F., Yaman F., Dogan O., Camlica H., Onat H.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.24, no.6, pp.570-575, 2001 (SCI-Expanded)
- LVI. **Thymidine labeling index in epithelial ovarian cancer**
Salihoglu Y., Bilir A., Aydiner A., Erkan M., Tuzlali S., Eralp Y.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, vol.75, no.2, pp.171-176, 2001 (SCI-Expanded)

Articles Published in Other Journals

- I. **Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak**
Sezer A., ÇİÇİN İ., Cakmak G. K., Gurdal S. O., Basaran G., Oyan B., ERALP Y., Gulluoglu B. M.
TURKISH JOURNAL OF SURGERY, vol.36, no.2, pp.147-163, 2020 (ESCI)
- II. **Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes**
Ordu C., Pilanci K. N., Alco G., Elbuken F., Koksall U. I., Ilgun S., Sarsenov D., Aydin A. E., Ozturk A., Erdogan Z. I., et al.
EUROPEAN JOURNAL OF BREAST HEALTH, vol.14, no.3, pp.173-179, 2018 (Peer-Reviewed Journal)
- III. **Impact of Personality Traits, Anxiety, Depression and Hopelessness Levels on Quality of Life in the Patients with Breast Cancer**
Izci F., Sarsenov D., Erdogan Z. I., Ilgun A. S., Celebi E., Alco G., Kocaman N., Ordu C., Ozturk A., Duymaz T., et al.
EUROPEAN JOURNAL OF BREAST HEALTH, vol.14, no.2, pp.105-111, 2018 (Peer-Reviewed Journal)
- IV. **Roles of Biopsychosocial Factors in the Development of Breast Cancer**
ÖZKAN M., Yildirim N., Disci R., Ilgun A. S., Sarsenov D., Alco G., Aktepe F., KALYONCU N., Izci F., Selamoglu D., et al.
EUROPEAN JOURNAL OF BREAST HEALTH, vol.13, no.4, pp.206-212, 2017 (Peer-Reviewed Journal)
- V. **The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus.**
Eralp Y.
Translational oncogenomics, vol.8, pp.1-7, 2016 (Peer-Reviewed Journal)
- VI. **The Relationship between Bone Mineral Density and Estrogen Receptor Positivity in Patients with Breast Cancer**
Iyigun Z. E., Pilanci K. N., Cabuk F. K., Ilgun S., Ordu C., Duymaz T., Alco G., Celebi F., Sarsenov D., Izci F., et al.
JOURNAL OF BREAST HEALTH, no.3, pp.119-122, 2016 (ESCI)
- VII. **The Prognostic Impact of Molecular Subtypes and Very Young Age on Breast Conserving Surgery in Early Stage Breast Cancer**
Ordu C., McGuire K., Alco G., Pilanci K. N., Koksall U. I., Elbuken F., Erdogan Z., Agacayak F., Ilgun S., Sarsenov D., et al.
CUREUS, vol.8, no.6, 2016 (Peer-Reviewed Journal)
- VIII. **True Local Recurrences after Breast Conserving Surgery have Poor Prognosis in Patients with Early Breast Cancer**
Sarsenov D., Ilgun S., Ordu C., Alco G., Bozdogan A., Elbuken F., Pilanci K. N., Agacayak F., Erdogan Z., Eralp Y., et al.
CUREUS, vol.8, no.3, 2016 (Peer-Reviewed Journal)

Refereed Congress / Symposium Publications in Proceedings

- I. **Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)**
Orer H. S., Nomak G., Oksuzoglu B., Senturk R., ERALP Y., Yumuk F., Nomak H., Sanyal R.
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 9 - 13 September 2022
- II. **Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.**
Basaran G., Demirci U., Yildiz F., Cicin I., Aktas B. Y., Ozturk B., Goksu S. S., Coskun H. S., Oyan B., Sonmez O., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 May 2020, vol.38
- III. **Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.**
Disel U., Kose F., Bilici A., ÖZGÜROĞLU M., Saglam S., Seker M., AKSOY S., Tek I., Eralp Y., Mandel N. M., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 May 2020
- IV. **Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey**
Demirci U., GÖKMEN E., Eralp Y., Gunduz S., SEZGİN GÖKSU S., KORKMAZ T., Kostek O., Turhal S., PAYDAŞ S., Topcu S., et al.
42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 9 - 14 December 2019, vol.80
- V. **Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2-inoperable locally advanced breast cancer (ABC): RIGHT choice study**
Lu Y., Malwinder S. S., Azim H., Eralp Y., Im S., Yap Y. S., Alfaro T. D., Gao M., El Saghir N. S.
European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapore, 22 - 24 November 2019
- VI. **Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?**
Kilickap S., Basal F. B., DEMİRKAZIK A., Gursay P., Demirci U., ERMAN M., Yumuk F., ÇAY ŞENLER F., Cakar B., ÇİÇİN İ., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, pp.637
- VII. **Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2-inoperable locally advanced or metastatic breast cancer: RIGHT choice study**
El Saghir N., Malwinder S., Azim H., Eralp Y., Im S., Yap Y. S., Alfaro T. D., Gao M., Lu Y.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, pp.140-141
- VIII. **The prognostic impact of chemotherapy induced amenorrhea in women treated with early stage breast cancer**
Ordu C., Pilanci K. N., Elbuken F., Alco G., Koksall U. I., Ilgun S., Sarsenov D., AYDIN A. E., Ozturk A., Erdogan Z. I., et al.
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8 - 12 September 2017
- IX. **Follow-up of chemotherapy induced changes in anti-Mullerian hormone, antral follicle number and ovary volume in premenopausal breast cancer patients**
Elbuken F., Ordu C., Sarsenov D., Ilgun S., Pilanci K., Erdogan Z., Agacayak F., Alco G., Ozturk A., Eralp Y., et al.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 7 - 11 October 2016, vol.27
- X. **Neoadjuvam kemoterapi öncesi biyopsi ile doğrulanmış aksiller metastazı olan hangi hasta grubunda tedavi sonrası aksiller diseksiyon göz ardı edilebilir?**
Karanlık H., Özgür İ., Bademler S., Şen F., Eralp Y., Fayda M., Küçük S., Aydın A.

20. Ulusal Cerrahi Kongresi, 2016, Antalya, Turkey, 13 - 17 April 2016, pp.1

- XI. **Metaplastic breast carcinoma versus triple negative breast cancer survival and response to treatment**
AYDINER A., ŞEN F., ÇİFTÇİ R., RÜMEYSA Ç., ERALP Y., SAİP P. M., KARANLIK H., MERDAN F.
MEDİCİNE, 01 December 2015
- XII. **Concomitant Chemoradiotherapy with Etoposide Cisplatin versus Docetaxel Cisplatin in Locally Advanced Non Small Cell Lung Cancer**
ERALP Y., ŞEN F., MAKBULE T., ÖZKAYA K., BERKER Ö., ORAL E. N., KAYTAN SAĞLAM E., FIRAT P., SAİP P. M., TOKER S. A., et al.
NSCLC, 09 September 2015
- XIII. **Does adjuvant chemotherapy induced amenorrhea effect survival in operated premenopausal breast cancer patients**
ORDU Ç., ALÇO G., KN P., S. İ., D. S., F. Ç., Zİ E., F. A., DEMİR G., ERALP Y., et al.
European Cancer Congress, 01 September 2015, vol.322
- XIV. **Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment**
G. A., ORDU Ç., D. S., F. Ç., ERDOĞAN Z., AĞACAYAK F., S. İ., TECİMER C., DEMİR G., ERALP Y., et al.
EUR J SUR ONCOL, 01 May 2015, vol.94
- XV. **Aksiller metastazı bulunan hangi hastalarda neoadjuvan kemoterapi sonrasında aksiller diseksiyon yapılmayabilinir?**
Karanlık H., Özgür İ., Fayda M., Yavuz E., Mudun A., Saip P. M., Eralp Y., Kurul S.
19. Ulusal Cerrahi Kongresi, Antalya, Turkey, 16 - 20 April 2014, pp.1-1751
- XVI. **The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer**
Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., TAŞ F., Aydinler A., Topuz E.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.174
- XVII. **Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER-2/neu in a murine mammary carcinoma model**
Eralp Y., Wang X., Wang J., Maughan M., Polo J., Lachman L.
27th Annual Charles A Colman San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 8 - 11 December 2004, vol.88

Metrics

Publication: 82

Citation (WoS): 747

Citation (Scopus): 751

H-Index (WoS): 17

H-Index (Scopus): 16